PROMISEPrecision Tobacco Treatment for Smoking Cessation in Oncology Patients
Usual care
+ Precision treatment
Behavior+1
+ Smoking
+ Health Behavior
Prevention Study
Summary
Study start date: September 11, 2025
Actual date on which the first participant was enrolled.This study focuses on helping cancer patients quit smoking by using a personalized approach to tobacco treatment. The goal is to provide each patient with the most effective and safest smoking cessation medication tailored just for them. The study involves cancer patients and their doctors, aiming to improve how often doctors recommend and patients use these treatments. This approach is important because quitting smoking can significantly improve a cancer patient's quality of life and survival. By integrating this personalized treatment into cancer care, the study hopes to enhance the effectiveness of smoking cessation efforts. In the study, doctors and their cancer patients are divided into two groups: one receiving standard care and the other receiving the personalized precision treatment. This personalized treatment involves sharing specific risks, benefits, and treatment recommendations with each patient to encourage them to follow through with quitting smoking. The study measures success by looking at how many patients receive and use the tobacco treatments, as well as how many successfully quit smoking. Other aspects such as the patients' quality of life and survival are also monitored. The study also examines how the personalized approach influences both doctors' and patients' attitudes towards smoking cessation and the overall implementation of the treatment.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.112 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Prevention Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 89 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Eligibility Criteria for Clinicians: * Clinician from participating oncology/hematology clinic * At least 18 years of age * Can speak and understand English Inclusion Criteria for Patients: * Patient at participating clinic * Age 18-89 years * Current smoking (average cigarettes per day ≥5) * Can speak and understand English * Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline Exclusion Criteria for Patients: * Active use of smoking cessation medication (within the past 30 days) * Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days) * Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy) * Patients who were deemed by the investigator to be ineligible for participation in the trial
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Active ComparatorGroup II
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location